REGN Pasatru Wins FDA Approval for FOP, Lesions Cut 90%

Update September 26, 2026: Mirum’s Atebrioz (zilurgisertib), the oral ALK2 inhibitor this article flagged as the swing catalyst, was approved September 25 — one day ahead of its September 26 PDUFA (see our Atebrioz coverage). Pasatru now launches into a three-way FOP market alongside Atebrioz and Ipsen’s Sohonos.

The FDA approved Regeneron’s (REGN) Pasatru (garetosmab) on August 19 for adults with fibrodysplasia ossificans progressiva (FOP), an ultra-rare disorder in which bone forms inside muscle, tendons, and ligaments. It is the first FOP drug shown in a placebo-controlled trial to reduce both new heterotopic ossification (HO) lesions and clinician-assessed flare-ups. Regeneron shares closed at $826.64 on August 20.

The OPTIMA trial randomized adults to Pasatru 10 mg/kg, Pasatru 3 mg/kg, or placebo, dosed intravenously every four weeks for 56 weeks. Both doses cut new HO lesions dramatically: 90% at 10 mg/kg (2 lesions versus 19) and 94% at 3 mg/kg (1 versus 19), measured by CT scan. The drug is a fully human monoclonal antibody that neutralizes Activin A, the protein Regeneron scientists identified as the driver of rogue bone formation in FOP.

The disease burden is why any reduction matters. FOP affects roughly one in two million people, an estimated 800 patients in the US. HO of the jaw, spine, hip, and rib cage makes speaking, eating, walking, and breathing progressively harder, leading to wheelchair dependence and shortened survival. Pasatru caps a three-decade research effort and marks Regeneron’s move beyond its Dupixent and Eylea franchises into rare disease biology built on its VelocImmune platform.

Pasatru previously received Fast Track and Orphan Drug designation from the FDA. It is not the first FOP treatment, despite what “first and only” language in some coverage implies. Ipsen’s Sohonos (palovarotene), an oral retinoid, won approval in 2023 to reduce new HO volume. Pasatru’s edge is the flare-up data and the magnitude of lesion reduction, but the two are not head-to-head. The distinction matters to investors because Sohonos’s benefit-versus-risk profile has been debated, and Pasatru arrives as a monthly infusion versus a daily pill.

The competitive race is not over. Mirum and Incyte’s zilurgisertib (Atebrioz), an oral ALK2 inhibitor, won approval September 25 — one day ahead of its September 26 PDUFA date. Both drugs hit the same signaling axis, with Pasatru blocking the Activin A ligand and zilurgisertib blocking the ALK2 receptor. FOP is a market measured in hundreds of patients, so pricing will be steep; for how ultra-rare drugs price and what insurers tolerate, see the orphan drug pricing guide. Regeneron plans an OPTIMA 2 trial in adolescents and children later this year.

What to watch next: launch execution against Atebrioz, which was approved September 25. Pasatru now faces an oral rival weeks after launch in a three-way market with Atebrioz and Sohonos. Read our Atebrioz coverage for the full case.

Source: OPTIMA trial (garetosmab in FOP) on ClinicalTrials.gov (NCT05394116)

What It Means for the Trade

Regeneron just closed one of the cleaner rare-disease catalysts of the year — a first-in-class antibody approval on placebo-controlled data in a disease with zero prior antibody competition — and the market barely re-rated an $800-plus stock, which is the correct arithmetic. FOP at roughly 800 U.S. patients is strategically valuable but financially rounding-error for a company of REGN’s size. What the approval actually does is validate the VelocImmune rare-disease engine and the Activin A biology, which is where the optionality sits.

The near-term swing event has now resolved: Mirum/Incyte’s oral ALK2 inhibitor (Atebrioz) was approved September 25, so Pasatru launches into a three-way market with a daily-pill rival at exactly the wrong moment — before it has established prescribing patterns. Pasatru’s commercial footprint this year is measured in hundreds of patients, so watch OPTIMA 2 (adolescents and children) as the franchise-expansion read.

For positioning: this is a hold-and-harvest setup, not a momentum trade. The Regeneron bull case runs through Dupixent’s ongoing expansion and pipeline reads; Pasatru is proof of breadth, not the engine.

Risks and What Could Go Wrong

1. Atebrioz’s September 25 approval. The oral ALK2 inhibitor cleared one day early, so the convenience pitch writes itself for less-advanced patients and payer conversations now span three FOP drugs.
2. Ultra-rare economics. Even at orphan prices, 800 patients cannot move REGN’s numbers; any execution stumble here is reputational, not financial.
3. Infusion friction. Monthly IV dosing in patients with locked jaws, frozen spines, and fusion-prone limbs is an administration challenge that trial settings do not fully capture — real-world uptake could undershoot.
4. Pediatric data risk. OPTIMA 2 in adolescents and children is the franchise-expansion leg; FOP’s most devastating progression happens early, and a delay or miss there caps the therapy’s impact story.

Net: elite biology, approved cleanly, strategically valuable, financially minor. The September 26 catalyst has resolved with Atebrioz’s approval; hold the rest.